127 related articles for article (PubMed ID: 38401646)
1. Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Januzzi JL; Liu Y; Sattar N; Yavin Y; Pollock CA; Butler J; Jardine M; Heerspink HJL; Masson S; Breyer M; Hansen MK
Am Heart J; 2024 May; 271():38-47. PubMed ID: 38401646
[TBL] [Abstract][Full Text] [Related]
2. Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points.
Mohebi R; Liu Y; Hansen MK; Yavin Y; Sattar N; Pollock CA; Butler J; Jardine M; Masson S; Heerspink HJL; Januzzi JL
Clin J Am Soc Nephrol; 2024 Apr; 19(4):429-437. PubMed ID: 38099944
[TBL] [Abstract][Full Text] [Related]
3. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK
Circulation; 2023 Aug; 148(8):651-660. PubMed ID: 37603600
[TBL] [Abstract][Full Text] [Related]
5. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
Mohebi R; Liu Y; Hansen MK; Yavin Y; Sattar N; Pollock CA; Butler J; Jardine M; Masson S; Heerspink HJL; Januzzi JL
Cardiovasc Diabetol; 2023 Jul; 22(1):176. PubMed ID: 37438734
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
7. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M;
Am J Kidney Dis; 2023 Jul; 82(1):84-96.e1. PubMed ID: 36889425
[TBL] [Abstract][Full Text] [Related]
8. Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.
Rambod M; Heine GH; Seiler S; Dominic EA; Rogacev KS; Dwivedi R; Ramezani A; Wing MR; Amdur RL; Fliser D; Raj DS
Atherosclerosis; 2014 Oct; 236(2):360-5. PubMed ID: 25128974
[TBL] [Abstract][Full Text] [Related]
9. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T; Mori-Anai K; Kawaguchi Y; Katsumata H; Tsuda H; Iida M; Arakawa K; Jardine MJ
J Diabetes Investig; 2022 Jan; 13(1):54-64. PubMed ID: 34212533
[TBL] [Abstract][Full Text] [Related]
10. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
[TBL] [Abstract][Full Text] [Related]
11. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction.
Kodama Y; Kitta Y; Nakamura T; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Mende A; Kobayashi T; Kugiyama K
J Am Coll Cardiol; 2006 Jul; 48(1):43-50. PubMed ID: 16814647
[TBL] [Abstract][Full Text] [Related]
14. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
Aminuddin NA; Sutan R; Mahdy ZA; Rahman RA; Nasuruddin DN
PLoS One; 2022; 17(3):e0265080. PubMed ID: 35275947
[TBL] [Abstract][Full Text] [Related]
16. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.
Shinohara S; Uchida Y; Kasai M; Sunami R
Hypertens Pregnancy; 2017 Aug; 36(3):269-275. PubMed ID: 28737473
[TBL] [Abstract][Full Text] [Related]
17. An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease.
Matsumoto T; Uemura S; Takeda Y; Matsui M; Okada S; Nishida T; Soeda T; Okayama S; Somekawa S; Ishigami K; Onoue K; Kawata H; Kawakami R; Horii M; Saito Y
Intern Med; 2013; 52(10):1019-27. PubMed ID: 23676585
[TBL] [Abstract][Full Text] [Related]
18. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
Theilade S; Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
Diabet Med; 2012 Mar; 29(3):337-44. PubMed ID: 21988672
[TBL] [Abstract][Full Text] [Related]
20. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies.
Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
